Summit Therapeutics stock rating reaffirmed at Citizens on trial data

Summit Therapeutics reported that Akeso's HARMONi-GI1 study showed ivonescimab plus chemotherapy improved overall survival in advanced biliary tract cancer compared to durvalumab plus chemotherapy, reducing death risk by 25% (OS hazard ratio 0.75). Summit plans a U.S. registration-enabling study starting in Q4 2026.

Jefferies reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) with a $30 price target, citing encouraging pipeline readthroughs and positive data from the European Society for Medical Oncology conference. The stock is currently trading at $14.88, suggesting a potential upside of nearly 100%. Analysts have mixed views, with some highlighting the company's strategic collaboration with AstraZeneca and others expressing skepticism.

Stifel maintained a Buy rating and $38.00 price target for Summit Therapeutics (SMMT) after positive clinical trial data from partner Akeso's HARMONi-GI1 study. The stock is down 47% from its 52-week high, with a market cap of $12.4B. Analysts' price targets range from $11.90 to $43.73. The trial showed promising results for ivonescimab in first-line biliary tract cancer, with a hazard ratio of 0.75. Summit also received a $2B investment from AstraZeneca for cancer treatment development.

AstraZeneca's stomach cancer drug doubled survival, Eli Lilly's lung cancer treatment showed 62% tumor shrinkage, Moderna/Merck's vaccine reduced recurrence risk by 42%, Amgen's therapy extended survival, and Roche's drug outperformed rivals. U.S. stocks fell due to AI jitters and oil price spikes, with Fed rate decisions looming. Earnings reports from Visa, Alphabet, and others are upcoming. TransDigm's stock declined despite strong sales due to higher interest rates and oil price concerns.

Summit Therapeutics reported positive Phase 3 trial results for Ivonescimab in advanced biliary tract cancer. Several pharma companies, including Novartis, Biogen, GSK, Lilly, Merck, and others, are set to report earnings this week. Beam Therapeutics and Benitec Biopharma will present early gene-therapy data. Inovio and Agios await FDA decisions on their respective treatments.

Summit Therapeutics (NASDAQ: SMMT) reported positive phase 3 trial results for ivonescimab, showing improved survival rates in advanced biliary tract cancer. The drug reduced the risk of disease progression or death by 39% and achieved tumor shrinkage in 53.8% of patients. Summit trades at a high P/S ratio of 560x, reflecting growth expectations despite being unprofitable. Insiders have bought $103.6 million in shares over the past year.